1. What data in particular will be shared?
   Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
   


2. What additional supporting information will be shared?
   Response -  Study Protocol
   Response -  Statistical Analysis Plan
   Response - Clinical Study Report
   
   
3. Who will be able to view these files?
   Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
   


4. For what types of analyses will this data be available?
   Response - To achieve aims in the approved proposal.
   


5. By what mechanism will data be made available?
   Response - Proposals should be directed to [bkmeher187@yahoo.co.in].
   


6. For how long will this data be available start date provided 01-08-2029 and end date provided 31-07-2032?
   Response - Beginning 3 months and ending 5 years following article publication.
   


7. Any URL or additional information regarding plan/policy for sharing IPD? 
   Additional Information - NIL

Rationale/Gaps in Existing Knowledge: Viral pneumonia is a critical issue in children in the PICU. Adenovirus causes up to 10% of global respiratory infections in children, with high mortality in infants and immunocompromised patients. IVIG may help due to its immunomodulatory effects, but no formal guidelines or trials exist for its use in adenoviral pneumonia.

Novelty: IVIG in severe adenoviral pneumonia could reduce morbidity and mortality with minimal toxicity.

Objectives: Compare morbidity and mortality in children with adenoviral pneumonia receiving IVIG versus those not receiving IVIG.

Methods: Children with suspected viral pneumonia needing respiratory support will receive oxygen, ventilators, drugs, fluids, and antibiotics. Nasopharyngeal swabs or aspirates will be collected from non-ventilated children, and mini-BAL samples from those with invasive ventilation. These will be tested for adenovirus using the BIOFIRE panels. Participants will be randomly assigned to receive either IVIG (2g/kg over 2 days) or a placebo. The primary endpoint is the time to clinical improvement up to day 28, defined by a reduction of two levels on a six-point ordinal scale or discharge alive. Secondary outcomes include mortality, ventilator support, vasopressor therapy, hospitalization duration, organ dysfunction, and other complications. Primary analysis will use an intention-to-treat basis, and safety analysis will include all who started treatment. This trial will be registered with ClinicalTrials.gov.

Expected Outcomes: Differences in the outcome between the two groups will provide useful information for the use and recommendation of intravenous immunoglobulin in severe adenoviral pneumonia in children.